logo
Plus   Neg
Share
Email

Stock Alert: Jounce Therapeutics Touches New High

Shares of clinical-stage immunotherapy company, Jounce Therapeutics, Inc. (JNCE) are rising more than 14% Tuesday morning and touched a new high at $10.25.

The stock more than doubled from early this month, following Gilead Sciences' investment in the company to develop and commercialize Jounce's novel immunotherapy program, JTX-1811.

Gilead has agreed to pay $85 million upfront and $35 million in equity investment.

JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Australia's Westpac Group (WBC.AX, WBK) agreed to pay A$1.3 billion to settle the civil proceedings over money laundering and child exploitation allegations brought by financial crimes regulator AUSTRAC. Amazon's much-awaited Prime Day shopping event will take place in mid-October, according to multiple reports. The annual sale event will reportedly kick off in the U.S. on Tuesday, October 13. Amazon Prime Day, the company's biggest, global shopping event of the year, is usually held in the U.S. in mid-July. However, the e-commerce giant confirmed in July that it is delaying this year's event. Walmart Foundation, Cargill and McDonald's said they will invest more than $6 million in a million-acre grazing initiative to help restore grasslands and address the issue of climate change. The initiative, led by the World Bank, aims to make lasting improvements to the grasslands of the Northern Great Plains. The new program is known as the Ranch Systems and Viability Planning or RSVP network.
Follow RTT